proteins regulating sodium channel function, such as glycerol-3-phosphate dehydrogenase-1-like enzyme and small subunits of sodium channel (hNavβ1 and hNavβ3) also are associated with BrS and the loss of hNav1.5 function. [16] [17] [18] Excitation-contraction coupling is indispensable for the excitation of cardiomyocytes and is regulated by the functional association of T-tubules and sarcoplasmic reticulum. 19 It has been reported that abnormalities of T-tubules or sarcoplasmic reticulum can cause ventricular arrhythmias. [20] [21] [22] One of the components of T-tubules and sarcoplasmic reticulum is sarcolemmal membrane-associated protein (SLMAP), of which the gene SLMAP maps to chromosome 3p14.3-21.2 and encodes several isoforms of SLMAP via alternative splicing. 23 SLMAP is composed of several functional domains, including a forkhead-associated domain, a RecN domain, 2 leucine zipper domains, and a tail-anchor domain that is expressed as a mutually exclusive TM1 or TM2 domain. The tailanchor domains play a pivotal role in subcellular targeting of SLMAP. 24 It is known that a ubiquitously expressed isoform, SLMAP3, is encoded by an open reading frame from the start codon in exon 1, whereas the other isoforms, SLMAP1 and SLMAP2, expressed abundantly in striated muscles including heart, are encoded by the other overlapping reading frames from different start codons. 25 Although the functional involvement of SLMAP in cardiac pathophysiology is largely unknown, SLMAP is a candidate gene to search for mutations in arrhythmias including BrS of unknownetiology.
In this study, we analyzed BrS patients for SLMAP mutations and investigated the functional significance of the identified mutations. The disease-associated SLMAP mutations decreased the cell surface expression of hNav1.5 and reduced the I Na in transfected cells. This is the first report demonstrating the functional association of SLMAP with hNav1.5 and a novel pathogenic substrate for BrS.
Materials and Methods

Subjects
We studied 190 genetically unrelated patients with BrS. All patients manifested with a BrS diagnostic ECG pattern and were all free from mutations in SCN5A (BrS1). 26 Control subjects were 94 to 380 ethnic-matched healthy individuals. Blood sample was obtained from each subject after an informed consent for gene analysis was given. Data from public available databases as the 1000 genome project (http://www.1000genomes.org/) also were analyzed as controls. The research protocol was approved by the Ethics Review Committee of Medical Research Institute, Tokyo Medical and Dental University, the Mayo Foundation Institutional Review Board, and the Medical Ethical Committee of Fondazione IRCCS Policlinico San Matteo.
Mutational Analysis of SLMAP in BrS
Genomic DNA extracted from peripheral blood leukocytes of each individual was subjected to polymerase chain reaction using primer pairs for SLMAP (online-only Data Supplement Table I ). Polymerase chain reaction products from Japanese patients were analyzed by direct sequencing method, whereas those from white patients underwent denaturing high-performance liquid chromatography and direct sequencing. 27 The sequencing of polymerase chain reaction products was performed using Big Dye Terminator version 3.1 (Applied Biosystems) and ABI3100 DNA analyzer (Applied Biosystems). The patients carrying rare nonsynonymous variations also were analyzed for mutations in all known BrS susceptibility genes (online-only Data Supplement Table II) .
Constructs for SLMAP, hNavβ1, and hNav1.5
We obtained cDNA fragments for human SLMAP by reverse-transcription polymerase chain reaction from human heart cDNA. Wildtype (WT) cDNA fragment for SLMAP with TM1 or TM2 domain were amplified, and equivalent cDNA fragments containing a G-to-A substitution in codon 269 (for V269I), a C-to-A substitution in codon 288 (for H288Y), or an A-to-C substitution at codon 710 (for E710A) were created by the primer-mediated mutagenesis method (online-only Data Supplement Table III ). The cDNA fragments of SLMAP were cloned into pEGFP-C1 for EGFP-SLMAP, pcDNA3.1 for pcDNA3.1-SLMAP, and pIRES-CD8 for pIRES-CD8-SLMAP. A cDNA fragment of hNavβ1 was cloned into pcDNA3.1-myc, and into His-B to obtain myc, His-hNavβ1. The cDNA fragment of human SCN5A was a gift from Dr A.L. George (Vanderbilt University, Nashville, TN). A Flag-tagged hNav1.5 was constructed by inserting a Flag epitope (DYKDDDDK) into the extracellular linker 1 between S1 and S2 in D1 domain after the position of aa154 in the hNav1.5 construct (L1-Flag-hNav1.5). 28 All constructs were sequenced to ensure that no errors were introduced.
Immunofluorescence Microscopy
HEK293 or H9c2 cells were seeded onto culture slides (BD Biosciences); 24 hours later, L1-Flag-hNav1.5 plus each EGFP-SLMAP with or without pcDNA3.1-SLMAP were transfected. After 48 hours of the transfection, the cells were permeabilized and incubated with the primary rabbit anti-Flag polyclonal Ab (Sigma) and secondary Alexa fluor 568 goat anti-rabbit IgG (Molecular Probes). Images of cells were collected and analyzed with LSM510 laser-scanning microscope. To quantify membrane expression of hNav1.5, fluorescence intensity at the entire cell area and the plasma membrane region (2 μm) in the middle xy images of z series stack were measured, and the ratios of peripheral to total cell area fluorescence intensity (PTAFI) were calculated as described previously. 16 Analyses of labeled cells were performed using ImageJ software (National Institutes of Health). 29
Silencing of Transfected SLMAP by Small Interfering RNA
Predesigned small interfering RNA (siRNA) for human SLMAP (siR-NA ID: s15435) and nonsilencing siRNA as a negative control were purchased from Ambion. HEK293 cells were seeded onto poly-D-Lysine-coated dishes or slides. After 24 hours, the cells were cotransfected with the combination of EGFP-SLMAP and L1-Flag-hNav1.5 with the predesigned siRNA or nonsilencing siRNA. After 48 hours of the transfection, the cells were lysed and subjected to Western blot analyses.
Electrophysiological Studies
We used the tsA-201 cell line, a derivative of HEK293 cell line, in our electrophysiological study, as described previously. 28 In brief, the cells were transfected transiently with either WT or mutant EGFP-SLMAP or pIRES-CD8-SLMAP in combination with pcDNA3.1-Nav1.5. Sodium currents were recorded from the cells that were positive for EGFP or labeled with CD8-Dynabeads using the whole-cell patch-clamp techniques.
Statistical Analysis
Numerical data were expressed as means±SEM. The normal distributions and equal variances of the data in this study were confirmed by using Shapiro-Wilk test or F test, respectively. Statistical differences were analyzed using 1-way ANOVA followed by Dunnett test and Student t test. P<0.05 was considered to be statistically significant.
Results
Mutational Analysis of SLMAP
We analyzed 190 BrS patients for mutations in SLMAP, and 8 synonymous and 5 nonsynonymous genetic variants were detected ( Table 1 and Figure 1A ). Among them, 5 variants had been registered in a public database of polymorphisms the single nucleotide polymorphism database (dbSNP) database; Table 1 ). A nonsynonymous variant p.Tyr68Phe (c.203A>T) was a polymorphism found in both patients and controls at similar frequencies in the Japanese population. The other 4 synonymous variants were rare but may not be disease-causing mutations, because no functional impact was deduced.
Three other variants were identified in the heterozygous state in each patient, p.Val269Ile (c.805G>A), p.His288Tyr (c.862C>T), and p.Glu710Ala (c.2129A>C) (online-only Data Supplement Figure IA and Table 1 ). The p.Val269Ile and p.Glu710Ala missense mutations (V269I and E710A, respectively) were found in a 46-year-old male patient and in a 57-year-old male patient, respectively, who both experienced syncope and showed spontaneous saddle-back (V269I) or coved-type (E710A) ST elevation on ECG, whereas the p.His288Tyr variant (H288Y) was found in a 51-year-old male patient who had development of a diagnostic BrS pattern only after the infusion of class Ic drugs. ECG records of the patients with V269I or E710A showed no apparent conduction delay ( Figure 1B and 1C, online-only Data Supplement Table IV ). In addition, both of them did not show obvious cardiac structural and functional abnormalities. All these substitutions were predicted to affect evolutionary conserved residues of SLMAP (online-only Data Supplement Figure IB) . Both V269I and H288Y should be expressed only in SLMAP3, whereas E710A would be expressed in all SLMAP isoforms ( Figure 1A ). Because these variants were found in Japanese patients, we analyzed 380 Japanese individuals selected at random. V269I and E710A were not detected in the controls, whereas H288Y was observed in 1 control (Table 1 ). In addition, V269I and E710A were absent among the 1094 individuals, descendants of various ancestries (381 European ancestry, 246 West African ancestry, 181 American ancestry, and 286 East Asian ancestry), whereas H288Y was reported in the 1000 genome project. The patients carrying these variants had no mutation in all the known BrS susceptibility genes and no family history of arrhythmia or sudden cardiac death. Family studies were not performed.
Decreased Cell Surface Expression of hNav1.5 in the Presence of Mutant SLMAPs
Because the majority of BrS-associated mutations are known to affect the hNav1.5 properties, including loss of cell surface expression, we tested whether the SLMAP mutations would affect the subcellular localization of hNav1.5. We examined expression of SLMAPs in cell lines available for transfection experiments and found the endogenous expression in HEK293, tsA-201, and H9c2 cells (online-only Data Supplement Figure II ). We then analyzed the cell surface expression of hNav1.5 in HEK293 cells cotransfected with L1-Flag-hNav1.5 and EGFP-SLMAP3 or EGFP-SLMAP1 with the TM1 or TM2 domain ( Figure 2 ). The PTAFI ratio of hNav1.5 in the cotransfected cells of L1-Flag-hNav1.5 and EGFP-SLMAP3-TM1-WT was similar to the PTAFI ratio in the transfectants of L1-Flag-hNav1.5 and EGFP-SLMAP3-TM2-WT. However, the PTAFI ratios in the transfected cells of L1-Flag-hNav1.5 with EGFP-SLMAP3-TM1-V269I, EGFP-SLMAP3-TM2-V269I, EGFP-SLMAP3-TM1-E710A, or EGFP-SLMAP3-TM2-E710A were significantly decreased, whereas the PTAFI ratios in the transfectants of L1-Flag-hNav1.5 with EGFP-SLMAP3-TM1-H288Y or EGFP-SLMAP3-TM2-H288Y were not significantly altered ( Figure  2 , online-only Data Supplement Table V) . E710A in SLMAP3 also should be expressed as E261A in SLMAP1, and we found that the PTAFI ratios in the L1-Flag-hNav1.5 transfected cells of either EGFP-SLMAP1-TM1-E261A or EGFP-SLMAP1-TM2-E261A were significantly decreased. To mimic a heterozygous state of SLMAP mutations, HEK293 cells were cotransfected with L1-Flag-hNav1.5, SLMAP3-TM1-WT, and each mutant SLMAP construct ( Figure 3 , online-only Data Supplement Table V ). The PTAFI ratios in the L1-Flag-hNav1.5-transfected cells with both WT and mutant SLMAP were similar to those in the L1-Flag-hNav1.5-transfected cells with each mutant SLMAP, suggesting that V269I and E710A reduced the surface expression of hNav1.5 by a dominant-negative mechanism.
Table 1. Sequence Variations in Exons of SLMAP Found in Brugada Syndrome Patients and Controls
We also investigated the reduction of hNav1.5 expression by the SLMAP mutations in a rat cardiomyocyte-derived cell line, H9c2. H9c2 cells were transiently transfected with L1-Flag-hNav1.5 and either WT or mutant EGFP-SLMAP3-TM1. It was found that V269I and E710A mutations, but not H288Y, diminished the surface expression of hNav1.5 (online-only Data Supplement Figure III ).
Silencing of Mutant SLMAPs Rescued the Cell Surface Expression of hNav1.5
To demonstrate the effect of SLMAP mutations on the surface expression of hNav1.5 by another method, we investigated whether silencing of the SLMAP mutants could rescue the decreased surface expression of hNav1.5. Silencing efficacy of predesigned siRNA for human SLMAP was evaluated, and it was Figure  4 ). HEK293 cells were transfected with the combinations of L1-Flag-hNav1.5, each EGFP-SLMAP construct, and predesigned siRNA to analyze the localization of hNav1.5. The PTAFI ratios in the transfected cells of L1-Flag-hNav1.5 with each EGFP-SLMAP3 or EGFP-SLMAP1 were not changed in the presence of nonsilencing siRNA ( Figure  4A ). The PTAFI ratios in the cells expressing L1-Flag-hNav1.5 with EGFP-SLMAP3 of either WT or H288Y with the TM1 or TM2 domain were not significantly different between the presence of predesigned siRNA and nonsilencing siRNA ( Figure 4B , online-only Data Supplement Table VI ). However, the PTAFI ratios in the cells expressing L1-Flag-hNav1.5 with EGFP-SLMAP3-TM1-V269I or EGFP-SLMAP3-TM2-V269I were significantly higher in the presence of predesigned siRNA than in the presence of nonsilencing siRNA. Similarly, the ratios in the transfectants of L1-Flag-hNav1.5 with EGFP-SLMAP3-TM1-E710A or EGFP-SLMAP3-TM2-E710A were significantly higher in the presence of predesigned siRNA than in the presence of nonsilencing siRNA. The predesigned siRNA also could suppress the impaired surface expression of hNav1.5 caused by the E261A mutation in SLMAP1 (online-only Data Supplement Figure V and online-only Data Supplement Table V ). The rescued expression levels, however, were similar to those in the L1-Flag-hNav1.5 transfected cells of EGFP-SLMAP1-WT with either predesigned siRNA or nonsilencing siRNA. These data indicated that the decreased surface expression of hNav1.5 was caused by the SLMAP mutations.
Altered Electrophysiological Characters Caused by the SLMAP Mutations
Because the impaired intracellular trafficking of hNav1.5 should result in the reduced hNav1.5 function, we investigated potential effects of the SLMAP mutants on the hNav1.5 kinetics. Wholecell patch-clamp recordings were obtained from tsA-201 cells transiently transfected with pcDNA3.1-hNav1.5 in combination with EGFP-SLMAP3-WT or EGFP-SLMAP1-WT carrying either TM1 or TM2 domain. Peak current density of I Na (pA/pF) recorded from the cells cotransfected with pcDNA3.1-hNav1.5 and EGFP-C1 was used as a control ( Figure 5 and online-only Data Supplement Figures V and VI) . It was found that the peak current densities recorded from the transfected cells of pcDNA3.1-hNav1.5 with EGFP-SLMAP3 or EGFP-SLMAP1 in the TM1 or TM2 domain were not significantly different from that of the control. In addition, they did not show any significant changes in the activation and inactivation kinetics of I Na and the time course of recovery from inactivation, as compared with EGFP only (Tables 2 and 3 ). When we analyzed the effect of mutant SLMAP3 carrying V269I, H288Y, or E710A on the kinetics of hNav1.5 in the transfected cells ( Figure 5 , online-only Data Supplement Figure V ), the peak current densities recorded from the cells cotransfected with pcDNA3.1-hNav1.5 and EGFP-SLMAP3-H288Y were similar to those recorded from the cells cotransfected with pcDNA3.1-hNav1.5 and EGFP-SLMAP3-WT. In clear contrast, the peak current densities of I Na recorded from the cells cotransfected with pcDNA3.1-hNav1.5 and EGFP-SLMAP3-V269I with TM1 or TM2 domain were significantly smaller than those recorded from the cells cotransfected with pcDNA3.1-hNav1.5 and EGFP-SLMAP3-WT with the TM1 or TM2 domain by 56.5% and 51.9%, respectively (Tables 2 and  3 ). In addition, the peak current densities recorded from the cells cotransfected with pcDNA3.1-hNav1.5 and EGFP-SLMAP3-E710A with the TM1 or TM2 domain were significantly smaller than those recorded from the cells cotransfected with pcDNA3.1-hNav1.5 and EGFP-SLMAP3-WT with the TM1 or TM2 domain by 49.7% and 40.7%, respectively. However, none of the EGFP-SLMAP3-V269I, EGFP-SLMAP3-H288Y, and EGFP-SLMAP3-E710A caused significant changes in the activation and inactivation kinetics of I Na and the time constants for recovery from inactivation.
We also investigated whether E261A mutation in SLMAP1 would show an effect on hNav1.5 kinetics as E710A mutation in SLMAP3 did. It was demonstrated that the peak current densities recorded from the cells cotransfected with pcDNA3.1-hNav1.5 and EGFP-SLMAP1-E261A were significantly lower than those recorded from the cells cotransfected with pcDNA3.1-hNav1.5 and EGFP-SLMAP1-WT by ≈40% without any significant changes in the activation and inactivation kinetics of I Na and the time constants for recovery from inactivation (Tables 2  and 3 , online-only Data Supplement Figure VI) .
To exclude a possibility that the EGFP fused to SLMAP might affect the function of SLMAP or hNav1.5, we recorded I Na from cells transiently transfected with pcDNA3.1-hNav1.5 and pIRES-CD8-SLMAP3 with or without mutation or variation (online-only Data Supplement Figure VII , online-only Data Supplement Table VII ). It was observed that pIRES-CD8-SLMAP3-V269I and pIRES-CD8-SLMAP3-E710A decreased the peak current densities of I Na to a similar extent as EGFP-fused SLMAPs. The effect of SLMAP mutations appeared to be exerted by a dominant-negative mechanism, as observed for the trafficking impairment.
Binding Between SLMAP and hNav1.5
Because the SLMAP mutations might modulate I Na through a physical interaction with hNav1.5, we investigated whether SLMAP bound hNav1.5. No direct interaction between SLMAP and hNav1.5 was found under the condition in which the binding of hNav1.5 and hNavβ1 could be detected (onlineonly Data Supplement Figure VIII ).
Discussion
Arrhythmias can be caused by mutations in the genes encoding ion channels producing action potentials. 30 In BrS, sodium current is more frequently affected than the other currents, such as calcium and potassium currents. 31 The affected sodium current is caused by mutations in the gene encoding hNav1.5, SCN5A, or genes for modifier proteins. 13, [16] [17] [18] Prevalence of SCN5A mutations in BrS is ≈20%, whereas the prevalence of EGFP-WT +pIRES-CD8-V269I A  0  1  7  E  -1  M  T  Y  8  8  2  H  -1  M  T  T  W  -1  M  T  T M1- V269I (c, d,  k, and l) , EGFP-SLMAP3-TM1 -H288Y (e,  f, m and n) , EGFP-SLMAP3-TM1-E710A (g, h, o, and p) , EGFP-SLMAP3-TM2-WT (q, r, y, and z) , EGFP-SLMAP3-TM2-V269I (s, t, a′, and b′') , EGFP-SLMAP3-TM2 -H288Y (u, v, c′, and d′) mutations in the other genes is relatively low. [31] [32] [33] [34] In the present study, genetic analysis of SLMAP revealed a low prevalence of mutation, 2 in 190 BrS patients. Functional studies of the mutations suggested that SLMAP might be a modifier protein of hNav1.5 function. Because hNav1.5 and modifier proteins compose the sodium channel complex to generate and regulate the sodium current, functional abnormality of any components of the complex might alter the electrophysiological characters of cardiomyocytes. 30 BrS-associated mutations in genes for the components of sodium channel complex usually result in loss of hNav1.5 function, including the voltage-dependent shift in the steady-state inactivation and activation profile, increased onset of inactivation, and decreased I Na . 14 It was reported that mutations in the gene for hNavβ1, an auxiliary subunit of the sodium channel, affected the modulation of hNav1.5 channel gating. 17 Here, we demonstrate that the SLMAP mutations do not affect the voltage dependence in inactivation or activation profiles, suggesting that the mutations do not biophysically alter the hNav1.5 channel gating. However, the SLMAP mutations exerted a biogenic effect by reducing the surface expression of hNav1.5, culminating in decreased peak sodium current density and BrS susceptibility.
EGFP-WT +pIRES-CD8-E710A
EGFP-V269I +pIRES-CD8-WT
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SLMAP is a member of tail-anchored proteins, which have a single TM domain at the C-terminal end to determine the subcellular localization. Tail-anchored proteins are involved in a variety of important cellular functions such as apoptosis, protein translocation, and membrane fusion in the organelles, where the proteins are anchored by the TM domain. 35 In the present study, we used SLMAPs carrying either the TM1 or TM2 domain and demonstrated that the mutation-related functional alteration could be observed similarly in any of the SLMAP isoforms with different TM domains, suggesting that the impaired hNav1.5 trafficking was attributable to the functional alterations of SLMAP in the endoplasmic reticulum, where SLMAP with either TM1 or TM2 domain could be localized. 24 Interestingly, SLMAP regulates the translocation of insulin-regulated glucose transporter GLUT4 from an intracellular compartment to the plasma membrane in adipose tissue, demonstrating the role of SLMAP in the intracellular trafficking. 36 We showed that the SLMAP mutants impaired the surface expression of hNav1.5. However, no direct binding of hNav1.5 and SLMAP was detected in this study, speculating that SLMAP might indirectly contribute to the action potential in cardiomyocytes by modulating hNav1.5 localization. It has been demonstrated that MOG1 binds hNav1.5, and a MOG1 mutation causes BrS via an intracellular trafficking defect. 13 Then, the mechanism of impaired hNav1.5 trafficking caused by the SLMAP mutations was different from that caused by the MOG1 mutation. Recently, it was reported that a Z-disc protein, ZASP, formed a macromolecular Figure 5 . Sodium currents recorded from tsA-201 cells cotransfected with Nav1.5 and sarcolemmal membrane-associated protein (SLMAP) 3-TM1 constructs. A, Representative sodium currents were recorded from transfected tsA-201 cells of pcDNA3.1-hNav1.5 with EGFP, EGFP-SLMAP3-wild type (WT), EGFP-SLMAP3-V269I, EGFP-SLMAP3-H288Y, or EGFP-SLMAP3-E710A with TM1 domain. These traces were recorded with the whole-cell configuration as shown in the inset. B, Current-voltage relationship for peak I Na . EGFP-SLMAP3-V269I and EGFP-SLMAP3-E710A showed a significant decline of peak current densities by 56.5% and 49.7% (n=11 for WT, n=9 for V269I, n=16 for E710A) at −30mV, whereas EGFP-SLMAP3-H288Y (n=7) did not alter the peak current density. C, The voltage dependence of steady-state fast inactivation and activation recorded from the transfected cells of pcDNA3.1-hNav1.5 in combination with EGFP, EGFP-SLMAP3-V269I, SLMAP3-H288Y, or EGFP-SLMAP3-E710A with TM1 domain were similar to that from the cells cotransfected with pcDNA3.1-hNav1.5 and EGFP-SLMAP3-WT with TM1 domain. D, Recovery from inactivation assessed by the double-pulse protocol was nearly identical among WT, V269I, H288Y, and E710A in SLMAP3. The 2-pulse protocol is shown in the inset. complex with hNav1.5, but there was no direct interaction between ZASP and hNav1.5, and a ZASP mutation disturbed the hNav1.5 function without affecting the localization of hNav1.5. 37 The function of hNav1.5 in cardiomyocytes may be regulated by a fine-tuning mechanism in which many proteins are directly or indirectly involved. Finally, although the loss of hNav1.5 function is often associated with prolongation of PR and QRS, no conduction delay was observed in ECGs from both patients carrying the SLMAP mutations. This might be attributable to the difference in severity of functional loss, or it might depend on the nature of affected genes. Further studies will be required to clarify the mechanisms causing the phenotypic difference in functional loss of hNav1.5.
In summary, we identified 2 SLMAP missense mutations associated with BrS, and the functional analyses indicated that mutant SLMAP biogenically impaired hNav1.5 trafficking. Like many of the BrS-associated auxiliary proteins, SLMAPmediated BrS joins the most common pathogenic mechanism of BrS, sodium current loss-of-function BrS.
